Akcije

Archive of Oncology
kako citirati ovaj članak
podeli ovaj članak

Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 9 od 10  
Back povratak na rezultate
2013, vol. 21, br. 3-4, str. 151-154
Hepatitis B reactivation after therapy for non-Hodgkin lymphoma: A case report with review of literature
(naslov ne postoji na srpskom)
aInstitut za onkologiju Vojvodine, Sremska Kamenica + Univerzitet u Novom Sadu, Medicinski fakultet
bKlinički centar Vojvodine, Klinika za infektivne bolesti, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet

e-adresagorana021@yahoo.com
Sažetak
(ne postoji na srpskom)
The natural course of hepatitis B virus (HBV) infection depends on the immune status of the host. In cancer patients, as the consequence of immune suppression due to chemotherapy and malignant disease itself, the balance between replicative potential of the virus and immune response of the host is disrupted leading to acute HBV infection or reactivation. We present a case of HBsAg positive, diffuse large B cell gastric lymphoma patient CD20+ staged IB, treated with six cycles of R-CHOP protocol and two cycles with rituximab monotherapy. Five months after the successful anti- cancer treatment, patient developed reactivation of chronic HBV infection (ten-fold increase in liver enzymes, HBsAg+, IgM antiHBc+, HBeAg(-), and HBV DNA 5×106 copies/ml). Antiviral therapy with lamivudine was started. Four weeks after the antiviral therapy initiation liver enzymes were in normal ranges. One year after the start of antiviral treatment HBV DNA PCR test did not detect any viral particles. The patient is in complete remission of malignant disease, and still receiving therapy with lamivudine. HBV screening in cancer patients is necessary in order to provide a prompt antiviral therapy and to prevent postponement or even cessation of planned anticancer treatment. HBsAg positive patients should start prophylactic antiviral treatment before the start of immunosuppressive treatment. Chemotherapy protocols consisting rituximab and corticosteroids significantly increase the risk of reactivation. If reactivation is diagnosed in course of chemotherapy, the therapy should be stopped and antiviral treatment should be applied as soon as possible. Treatment with lamivudine is continued at least 6 months after the chemotherapy end.
Reference
Artz, A.S., Somerfield, M.R., Feld, J.J., Giusti, A.F., Kramer, B.S., Sabichi, A.L., Zon, R.T., Wong, S.L. (2010) American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases. Journal of Clinical Oncology, 28(19): 3199-3202
Bae, J.H., Sohn, J.H., Lee, H.S., Park, H.S., Hyun, Y.S., Kim, T.Y., Eun, C.S., Jeon, Y.C., Han, D.S. (2012) A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier. Clinical and Molecular Hepatology, 18(2): 225
Ceballos-Viro, J., López-Picazo, J.M., Pérez-Gracia, J.L., Sola, J.J., Aisa, G., Gil-Bazo, I. (2009) Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small- cell lung cancer. World J Gastroenterol, 15(18); 2290-2
Cheng, A., Hsiung, C.A., Su, I., Chen, P., Chang, M., Tsao, C., Kao, W., Uen, W., Hsu, C., Tien, H., Chao, T., Chen, L., Whang-Peng, J. (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology (Baltimore, Md.), 37(6): 1320-8
Duberg, A., Nordström, M., Törner, A., Reichard, O., Strauss, R., Janzon, R., Bäck, E., Ekdahl, K. (2005) Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology, 41(3): 652-659
European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 57(1), 167-185, Epub 2012 Mar 20
Hanson, R.G., Peters, M.G., Hoofnagle, J.H. (1986) Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology (Baltimore, Md.), 6(2): 173-9
Hoofnagle, J.H. (2009) Reactivation of hepatitis B. Hepatology, 49(S5): S156-S165
Hui, C., Cheung, W.W.W., Zhang, H., Au, W., Yueng, Y., Leung, A.Y.H., Leung, N., Luk, J.M., Lie, A.K.W., Kwong, Y., Liang, R., Lau, G.K.K. (2006) Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg-Negative Patients Undergoing Cytotoxic Chemotherapy. Gastroenterology, 131(1): 59-68
Katz, L.H., Fraser, A., Gafter-Gvili, A., Leibovici, L., Tur-Kaspa, R. (2008) Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. Journal of viral hepatitis, 15(2): 89-102
Kusumoto, S., Tanaka, Y., Mizokami, M., Ueda, R. (2009) Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. International Journal of Hematology, 90(1): 13-23
Kusumoto, S., Tanaka, Y., Ueda, R., Mizokami, M. (2011) Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. Journal of Gastroenterology, 46(1): 9-16
Lau, G.K.K. (2008) Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatology International, 2(2): 152-162
Lavanchy, D. (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis, 11(2): 97-107
Lok, A.S.F., McMahon, B.J. (2009) Chronic hepatitis B. Hepatology, 50:1-36
Manzano-Alonso, M.L. (2011) Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World Journal of Gastroenterology, 17(12): 1531
Marcucci, F., Spada, E., Mele, A., Caserta, C.A., Pulsoni, A. (2012) The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review. Am J Blood Res., 2(1); 18-28
Marcucci, F., Mele, A. (2011) Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood, 117(6): 1792-1798
Mastroianni, C.M. (2011) Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World Journal of Gastroenterology, 17(34): 3881
Matičič, M., Poljak, M. (2010) Slovenske nacionalne usmeritve za preprečevanje reakti- vacije hepatitisa B pribolnikih, ki potrebujejo imunosupresivno zdravljenje. Slovene national guidelines for the prevention of hepatitis B reactivation in patients undergo- ing immunosuppressive. Zdravniški Vestnik, 79(9)
Pei, S., Chen, C., Lee, C., Wang, M., Ma, M., Hu, T., Kuo, C. (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Annals of Hematology, 89(3): 255-262
Torres, H.A., Davila, M. (2012) Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nature Reviews Clinical Oncology, 9(3): 156-166
Tur-Kaspa, R., Burk, R.D., Shaul, Y., Shafritz, D.A. (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA, 83(6): 1627-31
Yeo, W., Zee, B., Zhong, S., Chan, P.K.S., Wong, W., Ho, W.M., Lam, K.C., Johnson, P.J. (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. British Journal of Cancer, 90(7): 1306-1311
Yeo, W., Johnson, P.J. (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology, 43(2): 209-220
Zurawska, U., Hicks, L.K., Woo, G., Bell, C.M., Krahn, M., Chan, K.K., Feld, J.J. (2012) Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis. Journal of Clinical Oncology, 30(26): 3167-3173